Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIV001 in Basal Cell Carcinoma
NCT04470726Phase 1Completed
- Sponsor
- AiViva BioPharma
- Start
- Aug 2020
- Primary completion
- Jun 2023
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of AIV001 in basal cell carcinoma (BCC) (4 arms), sponsored by AiViva BioPharma. Primary endpoints: Number of adverse events at 119 days and Percentage of Histological Clearance at Day 126. Started Aug 2020; status: completed.
02
Drugs
AIV001
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT04470726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04470726.